Disease/Infection News

RSS

GENova Biotherapeutics files patent to combat breast cancer

(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has filed a patent for a potential blockbuster drug target that combats breast cancer.

10 Sep 2009

St. Vincent develops the first-ever HIV educational widget

Saint Vincent Catholic Medical Centers and the New York State Department of Health (DOH) today unveiled a novel Web-based technology to rapidly instruct health care providers throughout New York State about HIV diagnosis and prevention.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Survey reveals that hand-washing behaviors are poor despite H1N1 swine flu

With the White House estimating that 30 to 50 percent of Americans will contract H1N1 flu this season, you’d think more people would be focused on prevention.

10 Sep 2009

Swine flu more lethal than seasonal flu

Pandemic swine flu can infect cells deeper in the lungs than seasonal flu can, according to a new study published today in Nature Biotechnology.

10 Sep 2009

Swine flu more lethal than seasonal flu

Pandemic swine flu can infect cells deeper in the lungs than seasonal flu can, according to a new study published today in Nature Biotechnology. The researchers, from Imperial College London, say this may explain why people infected with the pandemic strain of swine-origin H1N1 influenza are more likely to suffer more severe symptoms than those infected with the seasonal strain of H1N1.

10 Sep 2009

Business operations to be hit in the event of H1N1 outbreak

In a national survey of businesses that looks at their preparations for a possible widespread H1N1 outbreak, Harvard School of Public Health (HSPH) researchers found that only one-third believe they could sustain their business without severe operational problems if half their workforce were absent for two weeks due to H1N1 (also known as "swine flu").

10 Sep 2009

Instant updates to parents on H1N1 influenza

Parents of school-aged children in every public and nonpublic school throughout Missouri will be able to receive instant updates about the H1N1 (Swine) flu as a result of a new, free service provided by the Missouri School Boards’ Association in collaboration with SchoolReach, a St. Louis-based school-to-parent notification and communications company. The service is available now to schools that do not already have an alert notification in place for parents.

10 Sep 2009

New form of malarial infection identified

Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection. The research, funded by the Wellcome Trust, confirms the potentially deadly nature of the disease.

10 Sep 2009

New Influenza A/H1N1 detection kit launched

QIAGEN, today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities in providing solutions for the global surveillance of the swine flu pandemic. QIAGEN’s new kit enables both the highly sensitive and specific detection of the novel Influenza A/H1N1, the virus that causes “swine flu”, as well as of all other known Influenza A and B virus strains.

10 Sep 2009

Preventive-care TB therapy is cost-effective for patients

University of Alabama at Birmingham (UAB) researchers have found that the cost of preventive antibiotic tuberculosis (TB) therapy for patients infected by human immunodeficiency virus (HIV) is generally less expensive than the reported cost of treating newly confirmed TB cases.

10 Sep 2009

Plant extract could lead to new drug development for H1N1

Scientists in China have discovered that roots of a plant used a century ago during the great Spanish influenza pandemic contains substances with powerful effects in laboratory experiments in killing the H1N1 swine flu virus that now threatens the world.

10 Sep 2009

Federal contract awarded to Children's Hospital of Philadelphia to study use of antibiotics in children

In the largest study of its kind, pediatric researchers at The Children's Hospital of Philadelphia have received a federal contract for a project to determine the most beneficial method of using antibiotics to treat urinary tract infections (UTIs) in children.

10 Sep 2009

ARUP Laboratories' scientist receives grant to research HIV therapies

ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that ARUP's Tanya Sandrock, PhD, Research & Development scientist, received a prestigious National Institutes of Health (NIH) grant to research additional HIV therapies.

9 Sep 2009

University of California receives $3.5 million grant from NIDA for AIDS vaccine research

The National Institute on Drug Abuse (NIDA) has awarded a $3.5 million grant for AIDS vaccine research to Phillip Berman, professor and chair of biomolecular engineering at the Jack Baskin School of Engineering at the University of California, Santa Cruz.

9 Sep 2009

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

9 Sep 2009

Cepheid's Flu Panel test to provide 45-minute identification of Flu A infection

Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types.

9 Sep 2009

HCV treatment study reveals low relapse rate of Pegetron

Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.

9 Sep 2009

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.

9 Sep 2009

MRSA awareness event to be held at Loyola University Chicago

MRSA Survivors Network, the Chicago-based nonprofit and official organization for World MRSA Day, along with fellow MRSA activists will lift the veil of secrecy surrounding MRSA. The history making inaugural kick-off event will be held at Loyola University Chicago on October 1st. The 2009 theme is "You Can Not Change What You Do Not Acknowledge."

9 Sep 2009